Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageSupernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Business segments
Jun 2026 · $219.1MThe company’s own SEC segment disclosure.
- Qelbree$89.2M41%
- GOCOVRI$37.5M17%
- Collaboration$35.4M16%
- Royalty License And Other$18.0M8%
- ONAPGO$13.5M6%
- Oxtellar XR$8.8M4%
- Other (3)$16.6M8%
Supernus Pharmaceuticals, Inc. (SUPN) reported revenue of $208M in Q1 2026 (quarter ended Mar 31, 2026), up 39% from the same quarter a year earlier. That came with a gross margin of 89% and net loss of $2.3M. For the full year FY2025, revenue was $719M (+8.6% year on year) and net income −$39M. Its largest product in Jun 2026 was Qelbree at $89M, 41% of the disclosed total, well ahead of GOCOVRI at 17%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #11 of 29 by Smart Score